Adriamycin cardiomyopathy: pathophysiology and prevention.

摘要: Current knowledge about adriamycin cardiomyopathy indicates that the major cause of this condition is increased oxidative stress although drug's antitumor action in patients may involve other mechanisms. Controversies different antioxidants preventing likely stem from fact must be effective both lipid and water phases, dose optimal, order to protective. Probucol, an antioxidant promoter endogenous antioxidants, one such agent. Conducting clinical trials with optimal probucol next step should make great anticancer drug safer more efficient fight against cancer.